26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study

Introduction: Scalp and facial hair regrew in alopecia areata (AA) patients in phase 2 of BRAVE-AA1 with baricitinib treatment, a JAK1/JAK2 inhibitor. At week 36 in the baricitinib 4-mg (N = 27), baricitinib 2-mg (N = 27), and placebo (N = 28) groups, 52%, 33%, and 4%, respectively, achieved a Severity of Alopecia Tool (SALT) score ≤20. A Clinician Reported Outcome (ClinRO) was used to grade eyebrow and eyelash involvement (0 = no hair loss, 3 = complete hair loss). For baricitinib 4-mg, 2-mg, and placebo, 39%, 29%, and 4%, respectively, achieved eyebrow score ≤1, and 60%, 40%, and 6%, respectively, achieved eyelash score ≤1. Here, we present median time to scalp, eyebrow, and eyelash improvement.